Drugs / AERAS-402
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01683773 | Sep 2012 → Aug 2014 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02375256 | Oct 2009 → Dec 2010 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1 | NCT02430506 | Sep 2008 → Jun 2009 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01198366 | Sep 2010 → Jan 2014 | tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01017536 | Dec 2009 → Mar 2012 | HIV infectious disease, tuberculosis | Aeras | Completed | No outcome recorded |
| Phase 2 | NCT02414828 | Oct 2008 → Jul 2010 | tuberculosis | Aeras | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01378312 Comparator | Feb → Oct 2011 | tuberculosis | Aeras | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AERAS 402 | “AERAS 402 is a live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens (Ag85A, Ag85B...” NCT01198366 ↗7“AERAS-402, a recombinant, replication-deficient adenovirus type 35 expressing the protective M. tuberculosis antigens Ag85A, Ag85B, and TB10.4” PMID 22296955 ↗ Jan 2012 |
| Modality | Vaccine | “adenovirus vaccine” NCT01198366 ↗ |
| Route | Intramuscular | “0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28” NCT01378312 ↗ |